Pre-diagnosis plasma cell-free DNA reveals early signatures of prostate and breast cancer risk up to eight years prior to clinical detection.
Genome-wide cell-free DNA (cfDNA) methylation profiling of 491 pre-diagnosis breast and prostate cancer plasma samples, some collected up to nine years before diagnosis, identifies early cancer-associated epigenetic alterations and predictive signatures. Differentially methylated regions were enriched in regulatory and...